BONEX Stock Overview
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bonesupport Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr232.00 |
| 52 Week High | kr255.00 |
| 52 Week Low | kr94.65 |
| Beta | 1.03 |
| 1 Month Change | 2.65% |
| 3 Month Change | 12.51% |
| 1 Year Change | 126.12% |
| 3 Year Change | 252.58% |
| 5 Year Change | 850.82% |
| Change since IPO | 625.00% |
Recent News & Updates
Recent updates
We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth
Mar 16
We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn
Nov 06Bonesupport Holding AB (publ)'s (STO:BONEX) Path To Profitability
Mar 31Insider Buying: The Bonesupport Holding AB (publ) (STO:BONEX) Chief Executive Officer Just Bought 4.0% More Shares
Mar 04One Bonesupport Holding AB (publ) (STO:BONEX) Analyst Just Cut Their EPS Forecasts
Mar 02What Kind Of Investors Own Most Of Bonesupport Holding AB (publ) (STO:BONEX)?
Feb 28We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn
Feb 07
Executive VP of R&D Michael Diefenbeck Just Bought 2.6% More Shares In Bonesupport Holding AB (publ) (STO:BONEX)
Jan 17The Bonesupport Holding (STO:BONEX) Share Price Has Gained 283%, So Why Not Pay It Some Attention?
Dec 31What Can We Make Of Bonesupport Holding's (STO:BONEX) CEO Compensation?
Dec 13Analysts Expect Breakeven For Bonesupport Holding AB (publ) (STO:BONEX) Before Long
Nov 25Shareholder Returns
| BONEX | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -5.9% | 2.5% | -0.7% |
| 1Y | 126.1% | -3.4% | 4.4% |
Return vs Industry: BONEX exceeded the Swedish Biotechs industry which returned -3.4% over the past year.
Return vs Market: BONEX exceeded the Swedish Market which returned 4.4% over the past year.
Price Volatility
| BONEX volatility | |
|---|---|
| BONEX Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: BONEX's share price has been volatile over the past 3 months.
Volatility Over Time: BONEX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 118 | Emil Billbäck | www.bonesupport.com |
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management.
Bonesupport Holding AB (publ) Fundamentals Summary
| BONEX fundamental statistics | |
|---|---|
| Market cap | kr15.25b |
| Earnings (TTM) | kr266.56m |
| Revenue (TTM) | kr655.75m |
57.2x
P/E Ratio23.3x
P/S RatioIs BONEX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BONEX income statement (TTM) | |
|---|---|
| Revenue | kr655.75m |
| Cost of Revenue | kr52.38m |
| Gross Profit | kr603.38m |
| Other Expenses | kr336.82m |
| Earnings | kr266.56m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 11, 2024
| Earnings per share (EPS) | 4.06 |
| Gross Margin | 92.01% |
| Net Profit Margin | 40.65% |
| Debt/Equity Ratio | 0% |
How did BONEX perform over the long term?
See historical performance and comparison